6 research outputs found
Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment
Abstract Background Few studies have evaluated the effect of statin exposure on metastasis risk among prostate cancer patients not receiving curative treatment. Methods We included men diagnosed with localized prostate cancer at an integrated health care system between 1997 and 2006 who did not receive curative treatment within 6âmonths of diagnosis. We followed these men until a metastatic event, disenrollment, death, or 12/31/2016. We collected all data from electronic health records supplemented by chart review. We used Cox regressions to examine the association between postâdiagnostic statin exposure and metastasis, controlling for clinical characteristics and preâdiagnostic statin exposure. Results There were 4245 men included. Mean age of diagnosis was 68.02âyears. 46.6% of men used statins after prostate cancer diagnosis. During followâup, 192 men developed metastasis (cumulative incidence rate: 14.5%). In the adjusted Cox model, statin use postâprostate cancer diagnosis was not significantly associated with a metastatic event (HRÂ =Â 0.97, 95% CIÂ =Â 0.69, 1.36). Preâdiagnostic statin use was also not associated with development of metastasis (HRÂ =Â 0.76, 95% CIÂ =Â 0.53, 1.10). We did not observe a doseâresponse for the proportion of personâtime atârisk postâprostate cancer diagnosis on statins (HRÂ =Â 0.98 per 10% increase in personâtime exposed [95% CIÂ =Â 0.93, 1.03]). Conclusions We did not find an inverse association between postâdiagnosis statin exposure and metastasis development in localized prostate cancer patients who did not receive active treatment. Our results did not offer support to the chemopreventive potential of postâdiagnostic statin use among men on active surveillance